|
1
|
Palade GE: Fine structure of blood
capillaries. J Appl Phys. 24:1424–1436. 1953.
|
|
2
|
Glenney JR Jr and Zokas L: Novel tyrosine
kinase substrates from Rous sarcoma virus-transformed cells are
present in the membrane skeleton. J Cell Biol. 108:2401–2408.
1989.
|
|
3
|
Sowa G, Pypaert M, Fulton D and Sessa WC:
The phosphorylation of caveolin-2 on serines 23 and 36 modulates
caveolin-1-dependent caveolae formation. Proc Natl Acad Sci USA.
100:6511–6516. 2003.
|
|
4
|
Song KS, Scherer PE, Tang Z, et al:
Expression of caveolin-3 in skeletal, cardiac, and smooth muscle
cells. Caveolin-3 is a component of the sarcolemma and
co-fractionates with dystrophin and dystrophin-associated
glycoproteins. J Biol Chem. 271:15160–15165. 1996.
|
|
5
|
Razani B, Combs TP, Wang XB, et al:
Caveolin-1-deficient mice are lean, resistant to diet-induced
obesity, and show hypertriglyceridemia with adipocyte
abnormalities. J Biol Chem. 277:8635–8647. 2002.
|
|
6
|
Rothberg KG, Heuser JE, Donzell WC, et al:
Caveolin, a protein component of caveolae membrane coats. Cell.
68:673–682. 1992.
|
|
7
|
Engelman JA, Zhang XL and Lisanti MP:
Sequence and detailed organization of the human caveolin-1 and -2
genes located near the D7S522 locus (7q31.1). Methylation of a CpG
island in the 5′ promoter region of the caveolin-1 gene in human
breast cancer cell lines. FEBS Lett. 448:221–230. 1999.
|
|
8
|
Kurzchalia T, Dupree P, Parton RG, et al:
VIP 21, A 21-kD membrane protein is an integral component of
trans-Golgi-network-derived transport vesicles. J Cell Biol.
118:1003–1014. 1992.
|
|
9
|
Glenney JR: The sequence of human caveolin
reveals identity with VIP 21, a component of transport vesicles.
FEBS Lett. 314:45–48. 1992.
|
|
10
|
Monier S, Parton RG, Vogel F, et al:
VIP21-caveolin, a membrane protein constituent of the caveolar
coat, oligomerizes in vivo and in vitro. Mol Biol
Cell. 6:911–927. 1995.
|
|
11
|
Arbuzova A, Wang L, Wang J, et al:
Membrane binding of peptides containing both basic and aromatic
residues. Experimental studies with peptides corresponding to the
scaffolding region of caveolin and the effector region of MARCKS.
Biochemistry. 39:10330–10339. 2000.
|
|
12
|
Luetterforst R, Stang E, Zorzi N, et al:
Molecular characterization of caveolin association with the Golgi
complex: identification of a cis-Golgi targeting domain in the
caveolin molecule. J Cell Biol. 145:1443–1459. 1999.
|
|
13
|
Schlegel A and Lisanti MP: A molecular
dissection of caveolin-1 membrane attachment and oligomerization.
Two separate regions of the caveolin-1 C-terminal domain mediate
membrane binding and oligomer/oligomer interactions in vivo.
J Biol Chem. 275:21605–21617. 2000.
|
|
14
|
Schlegel A, Schwab R, Scherer PE, et al: A
role for the caveolin scaffolding domain in mediating the membrane
attachment of caveolin-1. The caveolin scaffolding domain is both
necessary and sufficient for membrane binding in vitro. J
Biol Chem. 274:22660–22667. 1999.
|
|
15
|
Sargiacomo M, Scherer PE, Tang ZL, et al:
Oligomeric structure of caveolin: implications for caveolae
membrane organization. Proc Natl Acad Sci USA. 92:9407–9411.
1995.
|
|
16
|
Couet J, Li S, Okamoto T, et al:
Identification of peptide and protein ligands for the
caveolin-scaffolding domain. Implications for the interaction of
caveolin with caveolaeassociated proteins. J Biol Chem.
272:6525–6533. 1997.
|
|
17
|
Dvorak HF, Weaver VM, Tlsty TD, et al:
Tumor microenvironment and progression. J Surg Oncol. 103:468–474.
2011.
|
|
18
|
Chun TH, Hotary, et al: A pericellular
collagenase directs the 3-dimensional development of while adipose
tissue. Cell. 125:577–591. 2006.
|
|
19
|
Kan S, Konishi E, Arita T, et al:
Podoplanin expression in cancer-associated fibroblasts predicts
aggressive behavior in melanoma. J Cutan Pathol. Mar 3–2014.(Epub
ahead of print).
|
|
20
|
Zhou B, Chen WL, Wang YY, et al: A role
for cancer-associated fibroblasts in inducing the
epithelial-to-mesenchymal transition in human tongue squamous cell
carcinoma. J Oral Pathol Med. Mar 20–2014.(Epub ahead of
print).
|
|
21
|
Yu Y, Lee JS, Xie N, et al: Prostate
stromal cells express the progesterone receptor to control cancer
cell mobility. PLoS One. 9:e927142014.
|
|
22
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006.
|
|
23
|
De Wever O, Demetter P, Mareel M and
Bracke M: Stromal myofibroblasts are drivers of invasive cancer
growth. Int J Cancer. 123:2229–2238. 2008.
|
|
24
|
Sugimoto H, Mundel TM, Kieran MW and
Kalluri R: Identification of fibroblast heterogeneity in the tumor
microenvironment. Cancer Biol Ther. 5:1640–1646. 2006.
|
|
25
|
Erez N, Truitt M, Olson P, et al:
Cancer-associated fibroblasts are activated in incipient neoplasia
to orchestrate tumor-promoting inflammation in an
NF-kappaB-dependent manner. Cancer Cell. 17:135–147. 2010.
|
|
26
|
Ostman A: PDGF receptors-mediators of
autocrine tumor growth and regulators of tumor vasculature and
stroma. Cytokine Growth Factor Rev. 15:275–286. 2004.
|
|
27
|
Koleske AJ, Baltimore D and Lisanti MP:
Reduction of caveolin and caveolae in oncogenically transformed
cells. Proc Natl Acad Sci USA. 92:1381–1385. 1995.
|
|
28
|
Mercier I, Casimiro MC, Wang C, et al:
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1
downregulation and RB tumor suppressor functional inactivation.
Cancer Biol Ther. 7:1212–1225. 2008.
|
|
29
|
Sotgia F, Del Galdo F, Casimiro MC, et al:
Caveolin-1−/− null mammary stromal fibroblasts share
characteristics with human breast cancer-associated fibroblasts. Am
J Pathol. 174:746–761. 2009.
|
|
30
|
Sloan EK, Ciocca DR, Pouliot N, et al:
Stromal cell expression of caveolin-1 predicts outcome in breast
cancer. Am J Pathol. 174:2053–2043. 2009.
|
|
31
|
El-Gendi SM, Mostafa MF and El-Gendi AM:
Stromal caveolin-1 expression in breast carcinoma. Correlation with
early tumor recurrence and clinical outcome. Pathol Oncol Res.
18:459–69. 2012.
|
|
32
|
Witkiewicz AZ, Dasgupta A, Sammons S, et
al: Loss of stromal caveolin-1 expression predicts poor clinical
outcome in triple negative and basal-like breast cancers. Cancer
Biol Ther. 10:135–143. 2010.
|
|
33
|
Witkiewicz AK, Dasgupta A, Sotgia F, et
al: An absence of stromal caveolin-1 expression predicts early
tumor recurrence and poor clinical outcome in human breast cancers.
Am J Pathol. 74:2023–2034. 2009.
|
|
34
|
Simpkins SA, Hanby AM, Holliday DL, et al:
Clinical and functional significance of loss of caveolin-1
expression in breast cancer-associated fibroblasts. J Pathol.
227:490–498. 2012.
|
|
35
|
Zhao X, He Y, Gao J, et al: Caveolin-1
expression level in cancer associated fibroblasts predicts outcome
in gastric cancer. PLoS One. 8:e591022013.
|
|
36
|
He Y, Zhao X, Gao J, et al: Quantum
dots-based immunofluorescent imaging of stromal fibroblasts
caveolin-1 and light chain 3B expression and identification of
their clinical significance in human gastric cancer. Int J Mol Sci.
13:13764–13780. 2012.
|
|
37
|
Ayala G, Morello M, Frolov A, et al: Loss
of caveolin-1 in prostate cancer stroma correlates with reduced
relapse-free survival and is functionally relevant to tumour
progression. J Pathol. 23:77–87. 2013.
|
|
38
|
Di Vizio D, Morello M, Sotgia F, et al: An
absence of stromal caveolin-1 is associated with advanced prostate
cancer, metastatic disease and epithelial Akt activation. Cell
Cycle. 8:2420–2424. 2009.
|
|
39
|
Wu KN, Queenan M, Brody JR, et al: Loss of
stromal caveolin-1 expression in malignant melanoma metastases
predicts poor survival. Cell Cycle. 10:4250–5. 2011.
|
|
40
|
Witkiewicz AK, Kline J, Queenan M, et al:
Molecular profiling of a lethal tumor microenvironment, as defined
by stromal caveolin-1 status in breast cancers. Cell Cycle.
10:1794–1809. 2011.
|
|
41
|
Pavlides S, Tsirigos A, Vera I, et al:
Loss of stromal caveolin-1 leads to oxidative stress, mimics
hypoxia and drives inflammation in the tumor microenvironment,
conferring the ‘reverse Warburg effect’: a transcriptional
informatics analysis with validation. Cell Cycle. 9:2201–2219.
2010.
|
|
42
|
Bist A, Fielding CJ and Fielding PE: p53
regulates caveolin gene transcription, cell cholesterol, and growth
by a novel mechanism. Biochemistry. 39:1966–1972. 2000.
|
|
43
|
Mueller MM and Fusenig NE: Friends or
foes-bipolar effects of the tumour stroma in cancer. Nat Rev
Cancer. 4:839–849. 2004.
|
|
44
|
Martinez-Outschoorn UE, Trimmer C, Lin Z,
et al: Autophagy in cancer associated fibroblasts promotes tumor
cell survival: Role of hypoxia, HIF1 induction and NFκB. Cell
Cycle. 9:3515–3533. 2010.
|
|
45
|
Bartek J, Bartkova J and Lukas J: The
retinoblastoma protein pathway and the restriction point. Curr Opin
Cell Biol. 8:805–14. 1996.
|
|
46
|
Usui I, Haruta T, Iwata M, et al:
Retinoblastoma protein phosphorylation via PI 3-kinase and mTOR
pathway regulates adipocyte differentiation. Biochem Biophys Res
Commun. 275:115–120. 2000.
|
|
47
|
Gao N, Flynn DC, Zhang Z, et al: G1 cell
cycle progression and the expression of G1 cyclins are regulated by
PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J
Physiol Cell Physiol. 287:C281–C291. 2004.
|
|
48
|
Xu Y, Chen SY, Ross KN, et al: Androgens
induce prostate cancer cell proliferation through mammalian target
of rapamycin activation and post-transcriptional increases in
cyclin D proteins. Cancer Res. 66:7783–7792. 2006.
|
|
49
|
Mercier I, Camacho J, Titchen K, et al:
Caveolin-1 and accelerated host aging in the breast tumor
microenvironment: chemoprevention with rapamycin, an mTOR inhibitor
anti-aging drug. Am J Path. 181:278–292. 2012.
|
|
50
|
Ong CT, Khoo YT, Mukhopadhyay A, et al:
mTOR as a potential therapeutic target for treatment of keloids and
excessive scars. Exp Dermatol. 16:394–404. 2007.
|
|
51
|
Martinez-Outschoorn UE, Whitaker-Menezes
D, Pavlides S, et al: The autophagic tumor stroma model of cancer
or ‘battery-operated tumor growth’: A simple solution to the
autophagy paradox. Cell Cycle. 9:4297–4306. 2010.
|
|
52
|
Martinez-Outschoorn UE, Balliet RM,
Rivadeneira DB, et al: Oxidative stress in cancer associated
fibroblasts drives tumor-stroma co-evolution: A new paradigm for
understanding tumor metabolism, the field effect and genomic
instability in cancer cells. Cell Cycle. 9:3256–3276. 2010.
|
|
53
|
Garcia-Cardena G, Martasek P, Masters BS,
et al: Dissecting the interaction between nitric oxide synthase
(NOS) and caveolin. Functional significance of the nos caveolin
binding domain in vivo. J Biol Chem. 272:25437–40. 1997.
|
|
54
|
Pavlides S, Tsirigos A, Migneco G, et al:
The autophagic tumor stroma model of cancer: Role of oxidative
stress and ketone production in feuling tumor cell metabolism. Cell
Cycle. 9:3485–3505. 2010.
|
|
55
|
Trimmer C, Sotgia F, Whitaker-Menezes D,
et al: Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor
suppressors in the stromal microenvironment: a new genetically
tractable model for human cancer associated fibroblasts. Cancer
Biol Ther. 11:383–394. 2011.
|
|
56
|
Chiavarina B, Whitaker-Menezes D, Migneco
F, et al: HIF1-alpha functions as a tumor promoter in cancer
associated fibroblasts, and as a tumor suppressor in breast cancer
cells: Autophagy drives compartment-specific oncogenesis. Cell
Cycle. 9:3534–3551. 2010.
|
|
57
|
Capparelli C, Whitaker-Menezes D, Guido C,
et al: CTGF drives autophagy, glycolysis and senescence in
cancer-associated fibroblasts via HIF1 activation, metabolically
promoting tumor growth. Cell Cycle. 11:2272–2284. 2012.
|
|
58
|
Papandreou I, Cairns RA, Fontana L, et al:
HIF-1 mediates adaptation to hypoxia by actively downregulating
mitochondrial oxygen consumption. Cell Metab. 3:187–97. 2006.
|
|
59
|
Salceda S and Caro J: Hypoxia-inducible
factor 1alpha (HIF-1alpha) protein is rapidly degraded by the
ubiquitin-proteasome system under normoxic conditions. Its
stabilization by hypoxia depends on redox-induced changes. J Biol
Chem. 272:22642–22647. 1997.
|
|
60
|
Guzy RD, Hoyos B, Robin E, et al:
Mitochondrial complex III is required for hypoxia-induced ROS
production and cellular oxygen sensing. Cell Metab. 1:401–8.
2005.
|
|
61
|
Schofield CJ and Ratcliffe PJ: Signalling
hypoxia by HIF hydroxylases. Biochem Biophys Res Commun.
338:617–626. 2005.
|
|
62
|
Valko M, Rhodes CJ, Moncol J, et al: Free
radicals, metals and antioxidants in oxidative stress-induced
cancer. Chem Biol Interact. 160:1–40. 2006.
|
|
63
|
Pantuck AJ, An J, Liu H, et al:
NFkappaBdependent plasticity of the epithelial to mesenchymal
transition induced by Von Hippel-Lindau inactivation in renal cell
carcinomas. Cancer Res. 70:752–61. 2010.
|
|
64
|
Jung Y, Isaacs JS, Lee S, et al:
Hypoxia-inducible factor induction by tumour necrosis factor in
normoxic cells requires receptor-interacting protein-dependent
nuclear factor kappaB activation. Biochem J. 370:1011–1017.
2003.
|
|
65
|
Robinson JM and Gibbs M: Photosynthetic
intermediates, the warburg effect, and glycolate synthesis in
isolated spinach chloroplasts. Plant Physiol. 53:790–797. 1974.
|
|
66
|
Pavlides S, Whitaker-Menezes D,
Castello-Cros R, et al: The reverse Warburg effect Aerobic
glycolysis in cancer associated fibroblasts and the tumor stroma.
Cell Cycle. 8:3984–4001. 2009.
|
|
67
|
Witkiewicz AK, Whitaker-Menezes D,
Dasgupta A, et al: Using the ‘reverse Warburg effect’ to identify
high-risk breast cancer patients: stromal MCT4 predicts poor
clinical outcome in triple-negative breast cancers. Cell Cycle.
11:1108–1117. 2012.
|
|
68
|
Fernandez MA, Albor C, Ingelmo-Torres M,
et al: Caveolin-1 is essential for liver regeneration. Science.
313:1628–1632. 2006.
|
|
69
|
Yan H, Parsons DW, Jin G, et al: IDH1 and
IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009.
|
|
70
|
Fogal V, Richardson AD, Karmali PP, et al:
Mitochondrial p32 protein is a critical regulator of tumor
metabolism via maintenance of oxidative phosphorylation. Mol Cell
Biol. 30:1303–1318. 2010.
|
|
71
|
Elsheikh SE, Green AR, Rakha EA, et al:
Caveolin 1 and Caveolin 2 are associated with breast cancer
basal-like and triple-negative immunophenotype. Br J Cancer.
99:327–334. 2008.
|
|
72
|
Zuccari DAPC, Castro1 R, Gavioli AF, et
al: Immunohistochemical and molecular analysis of caveolin-1
expression in canine mammary tumors. Genet Mol Res. 11:153–165.
2012.
|
|
73
|
Sagara Y, Mimori K, Yoshinaga K, et al:
Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA
expression in human breast cancer. Br J Cancer. 91:959–965.
2004.
|
|
74
|
Gao X, Sun Y, Huang L, et al:
Down-regulation of caveolin-1 in gastric carcinoma and its clinical
biological significance. Ai Zheng. 24:311–316. 2005.(In
Chinese).
|
|
75
|
Yan J, Lu Q, Cai L, et al: Expression of
caveolin-1 gene in hepatitis B-related hepatocellular carcinoma and
the clinical significance thereof. Zhonghua Yi Xue Za Zhi.
88:3272–3274. 2008.(In Chinese).
|
|
76
|
Shi L, Chen XM, Wang L, et al: Expression
of caveolin-1 in mucoepidermoid carcinoma of the salivary glands:
correlation with vascular endothelial growth factor, microvessel
density, and clinical outcome. Cancer. 109:1523–1531. 2007.
|
|
77
|
Ando T, Ishiguro H, Kimura M, et al: The
overexpression of caveolin-1 and caveolin-2 correlates with a poor
prognosis and tumor progression in esophageal squamous cell
carcinoma. Oncol Rep. 18:601–609. 2007.
|
|
78
|
Yan J, Lu Q, Cai L, et al: Expression of
caveolin-1 gene in hepatitis B-related hepatocellular carcinoma and
the clinical significance thereof. Zhonghua Yi Xue Za Zhi.
88:3272–3274. 2008.
|
|
79
|
Tanase CP, Dima S, Mihai M, et al:
Caveolin-1 overexpression correlates with tumour progression
markers in pancreatic ductal adenocarcinoma. J Mol Histol.
40:23–29. 2009.
|
|
80
|
Cho DS, Yim H, Cho KS, et al: Impact of
caveolin-1 expression on the prognosis of transitional cell
carcinoma of the upper urinary tract. J Korean Med Sci. 23:296–301.
2008.
|
|
81
|
Yang G, Timme TL, Frolov A, et al:
Combined c-Myc and caveolin-1 expression in human prostate
carcinoma predicts prostate carcinoma progression. Cancer.
103:1186–1194. 2005.
|
|
82
|
Joshi B, Strugnell SS, Goetz JG, et al:
Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal
adhesion dynamics and tumor cell migration and invasion. Cancer
Res. 68:8210–8220. 2008.
|
|
83
|
Savage K, Lambros MB, Robertson D, et al:
Caveolin 1 is overexpressed and amplified in a subset of basal-like
and metaplastic breast carcinomas: a morphologic ultrastructural,
immunohistochemical, and in situ hybridization analysis. Clin
Cancer Res. 13:90–101. 2007.
|
|
84
|
Nam KH, Lee BL, Park JH, et al: Caveolin 1
expression correlates with poor prognosis and focal adhesion kinase
expression ingastric cancer. Pathobiology. 80:87–94. 2013.
|
|
85
|
Tang Y, Zeng X, He F, et al: Caveolin-1 is
related to invasion, survival, and poor prognosis in hepatocellular
cancer. Med Oncol. 29:977–984. 2012.
|
|
86
|
Tse EY, Ko FC, Tung EK, et al: Caveolin-1
overexpression is associated with hepatocellular carcinoma
tumourigenesis and metastasis. J Pathol. 226:645–653. 2012.
|
|
87
|
Hung KF, Lin SC, Liu CJ, et al: The
biphasic differential expression of the cellular membrane protein,
caveolin-1, in oral carcinogenesis. J Oral Pathol Med. 32:461–467.
2003.
|
|
88
|
Suzuoki M, Miyamoto M, Kato K, et al:
Impact of caveolin-1 expression on prognosis of pancreatic ductal
adenocarcinoma. Br J Cancer. 87:1140–1144. 2002.
|
|
89
|
Waalkes S, Eggers H, Blasig H, et al:
Caveolin 1 mRNA is overexpressed in malignant renal tissue and
might serve as a novel diagnostic marker for renal cancer. Biomark
Med. 5:219–225. 2011.
|
|
90
|
Davidson B, Nesland JM, Goldberg I, et al:
Caveolin-1 expression in advanced-stage ovarian carcinoma-a
clinicopathologic study. Gynecol Oncol. 81:166–171. 2001.
|
|
91
|
Liu HX, Xing LX, Wang HB, et al:
Relationship between expression of caveolin-1 and pERK1/2 and
prognosis in non-small cell lung cancer. Zhonghua Bing Li Xue Za
Zhi. 37:615–619. 2008.(In Chinese).
|
|
92
|
Zhang YX, Chen HL, Ye B, et al: Study on
expression and methylation of caveolin 1 gene in non-small cell
lung cancers. Zhonghua Bing Li Xue Za Zhi. 37:300–304. 2008.(In
Chinese).
|
|
93
|
Witkiewicz AK, Nguyen KH, Dasgupta A, et
al: Co-expression of fatty acid synthase and caveolin-1 in
pancreatic ductal adenocarcinoma: implications for tumor
progression and clinical outcome. Cell Cycle. 7:3021–3025.
2008.
|
|
94
|
Campbell L, Gumbleton M and Griffiths DFR:
Caveolin-1 overexpression predicts poor disease-free survival of
patients with clinically confined renal cell carcinoma. Br J
Cancer. 89:1909–1913. 2003.
|
|
95
|
Steffens Sandra, Schrader Andres J, Blasig
Hanna, et al: Caveolin 1 protein expression in renal cell carcinoma
predicts survival. BMC Urology. 11:252011.
|
|
96
|
Campbell L, Jasani B, Edwards K, et al:
Combined expression of caveolin-1 and an activated AKT/mTOR pathway
predicts reduced disease-free survival in clinically confined renal
cell carcinoma. Br J Cancer. 98:931–940. 2008.
|
|
97
|
Joo HJ, Oh DK, Kim YS, et al: Increased
expression of caveolin-1 and microvessel density correlates with
metastasis and poorprognosis in clear cell renal cell carcinoma.
BJU Int. 93:291–296. 2004.
|
|
98
|
Phuoc NB, Ehara H, Gotoh T, et al:
Immunohistochemical analysis with multiple antibodies in search of
prognostic markers for clear cellrenal cell carcinoma. Urology.
69:843–848. 2007.
|
|
99
|
Zhang ZB, Cai L, Zheng SG, et al:
Overexpression of caveolin-1 in hepatocellular carcinoma with
metastasis and worse prognosis: correlation with vascular
endothelial growth factor, microvessel density and unpaired artery.
Pathol Oncol Res. 15:495–502. 2009.
|
|
100
|
Yu JH, Wei Q, Qi FJ, et al: Significance
of caveolin-1 expression in primary lung cancer. Zhonghua Bing Li
Xue Za Zhi. 35:664–668. 2006.
|
|
101
|
Ho Chao-Chi, Huang Pei-Hsin, Huang
Hsin-Yi, et al: Up-regulated caveolin-1 accentuates the metastasis
capability of lung adenocarcinoma by inducing filopodia formation.
Am J Pathol. 161:1647–1656. 2002.
|
|
102
|
Zhan P, Shen XK, Qian Q, et al: Expression
of caveolin-1 is correlated with disease stage and survival in lung
adenocarcinomas. Oncol Rep. 27:1072–1078. 2012.
|
|
103
|
Yoo SH, Park YS, Kim HR, et al: Expression
of caveolin-1 is associated with poor prognosis of patients with
squamous cell carcinoma of the lung. Lung Cancer. 42:195–202.
2003.
|
|
104
|
Moon KC, Lee GK, Yoo SH, et al: Expression
of caveolin-1 in pleomorphic carcinoma of the lung is correlated
with a poor prognosis. Anticancer Res. 25:4631–467. 2005.
|
|
105
|
Ho CC, Kuo SH, Huang PH, et al: Caveolin-1
expression is significantly associated with drug resistance and
poor prognosis in advanced non-small cell lung cancer patients
treated with gemcitabine-based chemotherapy. Lung Cancer.
59:105–110. 2008.
|
|
106
|
Yang G, Truong LD, Wheeler TM and Thompson
TC: Caveolin-1 expression in clinically confined human prostate
cancer: a novel prognostic marker. Cancer Res. 59:5719–5723.
1999.
|
|
107
|
Satoh T, Yang G, Egawa S, et al:
Caveolin-1 expression is a predictor of recurrence-free survival in
pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer.
97:1225–1233. 2003.
|
|
108
|
Gumulec J, Sochor J, Hlavna M, et al:
Caveolin-1 as a potential high-risk prostate cancer biomarker.
Oncol Rep. 27:831–841. 2012.
|
|
109
|
Karam JA, Lotan Y, Roehrborn CG, et al:
Caveolin-1 overexpression is associated with aggressive prostate
cancer recurrence. Prostate. 67:614–22. 2007.
|
|
110
|
Yang G, Goltsov AA, Ren C, et al:
Caveolin-1 upregulation contributes to c-Myc-induced high-grade
prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer
Res. 10:218–229. 2012.
|
|
111
|
Steiner I, Jung K, Miller K, et al:
Expression of endothelial factors in prostate cancer: a possible
role of caveolin-1 for tumour progression. Oncol Rep. 27:389–395.
2012.
|
|
112
|
Tahir SA, Ren C, Timme TL, et al:
Development of an immunoassay for serum caveolin-1: a novel
biomarker for prostate cancer. Clin Cancer Res. 9:3653–3659.
2003.
|
|
113
|
Sugie S, Tsukino H, Yamauchi T, et al:
Functional polymorphism in the CAV1 T29107A gene and its
association with prostate cancer risk among Japanese men.
Anticancer Res. 33:1023–1027. 2013.
|
|
114
|
Langeberg WJ, Tahir SA, Feng Z, et al:
Association of caveolin-1 and -2 genetic variants and
post-treatment serum caveolin-1 with prostate cancer risk and
outcomes. Prostate. 70:1020–1035. 2010.
|
|
115
|
Barresi V, Giuffre’ G, Vitarelli E, et al:
Caveolin-1 immuno-expression in human gastric cancer:
histopathogenetic hypotheses. Virchows Arch. 453:571–578. 2008.
|
|
116
|
Sotgia F, Williams TM, Schubert W, et al:
Caveolin-1 deficiency (−/−) conveys premalignant alterations in
mammary epithelia, with abnormal lumen formation, growth factor
independence, and cell invasiveness. Am J Pathol. 168:292–309.
2006.
|
|
117
|
Cantiani L, Manara MC, Zucchini C, et al:
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src
activity and met signaling. Cancer Res. 67:7675–7685. 2007.
|
|
118
|
Senetta R, Miracco C, Lanzafame S, et al:
Epidermal growth factor receptor and caveolin-1 coexpression
identifies adult supratentorial ependymomas with rapid unfavorable
outcomes. Neuro Oncol. 13:176–183. 2011.
|
|
119
|
Ruan J and Weng ZL: Analysis of the
relationship between expression of caveolin-1 and prognosis in
bladder transitional cell carcinoma. Zhonghua Zhong Liu Za Zhi.
32:429–431. 2010.(In Chinese).
|
|
120
|
Qayyum T, Fyffe G, Duncan M, et al: The
interrelationships between Src, Cav-1 and RhoGD12 in transitional
cell carcinoma of the bladder. Br J Cancer. 13; 106:1187–1195.
2012.
|
|
121
|
Du ZM, Hu CF, Shao Q, et al: Upregulation
of caveolin-1 and CD147 expression in nasopharyngeal carcinoma
enhanced tumor cell migration and correlated with poor prognosis of
the patients. Int J Cancer. 125:1832–1841. 2009.
|
|
122
|
Rödel F, Capalbo G, Rödel C, et al:
Caveolin-1 as a prognostic marker for local control after
preoperative chemoradiation therapy inrectal cancer. Int J Radiat
Oncol Biol Phys. 73:846–852. 2009.
|
|
123
|
Wu HC, Chang CH, Tsou YA, et al:
Significant association of caveolin-1 (CAV1) genotypes with
prostate cancer susceptibility in Taiwan. Anticancer Res.
31:745–749. 2011.
|
|
124
|
Tsou YA, Tsai CW, Tsai MH, et al:
Association of caveolin-1 genotypes with nasopharyngeal carcinoma
susceptibility in Taiwan. Anticancer Res. 31:3629–3632. 2011.
|
|
125
|
Syeed N, Hussain F, Husain SA, et al:
5′-CpG island promoter hypermethylation of the CAV-1 gene in breast
cancer patients of Kashmir. Asian Pac J Cancer Prev. 13:371–375.
2012.
|
|
126
|
Shajahan AN, Goel S, de Assis S, et al:
Changes in mammary caveolin-1 signaling pathways are associated
with breast cancer risk in rats exposed to estradiol in utero or
during prepuberty. Horm Mol Biol Clin Investig. 2:227–234.
2010.
|
|
127
|
Lin M, DiVito MM, Merajver SD, et al:
Regulation of pancreatic cancer cell migration and invasion by RhoC
GTPase and caveolin-1. Mol Cancer. 4:212005.
|
|
128
|
Thomas S, Overdevest JB, Nitz MD, et al:
Src and caveolin-1 reciprocally regulate metastasis via a common
downstream signaling pathway in bladdercancer. Cancer Res.
71:832–841. 2011.
|
|
129
|
Arpaia E, Blaser H, Quintela-Fandino M, et
al: The interaction between caveolin-1 and Rho-GTPases promotes
metastasis by controlling the expression of alpha5-integrin and the
activation of Src, Ras and Erk. Oncogene. 31:884–896. 2012.
|
|
130
|
Chiu WT, Lee HT, Huang FJ, et al:
Caveolin-1 upregulation mediates suppression of primary breast
tumor growth and brain metastases by stat3 inhibition. Cancer Res.
71:4932–4943. 2011.
|
|
131
|
Zhang H, Su L, Müller S, et al:
Restoration of caveolin-1 expression suppresses growth and
metastasis of head and neck squamous cellcarcinoma. Br J Cancer.
99:1684–1694. 2008.
|
|
132
|
Yeh D, Chen C, Sun MZ, et al: Caveolin-1
is an important factor for the metastasis and proliferation of
human small cell lung cancer NCI-H446cell. Anat Rec (Hoboken).
292:1584–1592. 2009.
|
|
133
|
Urra H, Torres VA, Ortiz RJ, et al:
Caveolin-1-enhanced motility and focal adhesion turnover require
tyrosine-14 but not accumulation to the rear inmetastatic cancer
cells. PLoS One. 7:e330852012.
|
|
134
|
Duxbury MS, Ito H, Ashley SW, et al:
CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated
focal adhesion kinase phosphorylation inBxPC3 pancreatic
adenocarcinoma cells. J Biol Chem. 279:23176–82. 2004.
|
|
135
|
Meyer C, Liu Y, Kaul A, et al: Caveolin-1
abrogates TGF-β mediated hepatocyte apoptosis. Cell Death Dis.
4:e4662013.
|
|
136
|
Katsogiannou M, El Boustany C, Gackiere F,
et al: Caveolae contribute to the apoptosis resistance induced by
the alpha(1A)-adrenoceptor in androgen-independent prostate cancer
cells. PLoS One. 4:e70682009.
|
|
137
|
Rodriguez DA, Tapia JC, Fernandez JG, et
al: Caveolin-1-mediated suppression of cyclooxygenase-2 via a
beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced
prostaglandin E2 production and survivin expression. Mol Biol Cell.
20:2297–2310. 2009.
|
|
138
|
Palozza P, Sestito R, Picci N, et al: The
sensitivity to beta-carotene growth-inhibitory and proapoptotic
effects is regulated by caveolin-1 expression in human colon and
prostate cancer cells. Carcinogenesis. 29:2153–2161. 2008.
|
